Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SunWay Biotech CoROCO:1271 +0.17%82 Debt-to-EBITDA is 5.34 as of Jun. 2026, which is 394% above its 10-year median of 1.08. GuruFocus rates ROCO:1271 with a GF Score™ of 82/100 and a GF Value™ of NT$113.57 (Significantly Undervalued). The stock has 8 warning signs investors should review. Among 1,565 Consumer Packaged Goods companies, SunWay Biotech Co ranks worse than 84.09% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for SunWay Biotech Co's Debt-to-EBITDA or its related term are showing as below:
ROCO:1271'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.11 Med: 1.08 Max: 6.4
Current: 6.4
During the past 7 years, the highest Debt-to-EBITDA Ratio of SunWay Biotech Co was 6.40. The lowest was 0.11. And the median was 1.08.
ROCO:1271's Debt-to-EBITDA is ranked worse than 84.09% of 1565
companies
in the Consumer Packaged Goods industry
Industry Median: 2.08
vs ROCO:1271: 6.40
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SunWay Biotech Co Debt-to-EBITDA Related Terms
SunWay Biotech Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for SunWay Biotech Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, SunWay Biotech Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SunWay Biotech Co Debt-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, SunWay Biotech Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SunWay Biotech Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
SunWay Biotech Co (ROCO:1271) has a Debt-to-EBITDA of 5.34 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SunWay Biotech Co. This is 394% above median its historical median of 1.08. Over the past decade, SunWay Biotech Co's Debt-to-EBITDA has ranged from 0.11 to 6.40. According to the industry distribution chart, SunWay Biotech Co ranks #1316 out of 1565 companies in the Consumer Packaged Goods industry, placing it in the top 84.1%.
Is SunWay Biotech Co's Debt-to-EBITDA too high?
SunWay Biotech Co's current Debt-to-EBITDA of 5.34 is 394% above median its 10-year median of 1.08. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 6.40. The Consumer Packaged Goods industry median Debt-to-EBITDA is 2.08. SunWay Biotech Co's value of 5.34 is 156.7% above this industry median. Based on the distribution chart, SunWay Biotech Co ranks #1316 out of 1565 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, SunWay Biotech Co has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SunWay Biotech Co's Debt-to-EBITDA compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, SunWay Biotech Co ranks #1316 out of 1565 companies for Debt-to-EBITDA. This places SunWay Biotech Co in the lower half of its industry. The industry median Debt-to-EBITDA is 2.08. SunWay Biotech Co's value of 5.34 is 156.7% above this benchmark. Historically, SunWay Biotech Co's own Debt-to-EBITDA has ranged from 0.11 to 6.40 over the past decade. While the company's 10-year median is 1.08 vs. the industry median of 2.08, SunWay Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.08, based on 1,565 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SunWay Biotech Co's current Debt-to-EBITDA of 5.34 is 156.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SunWay Biotech Co. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SunWay Biotech Co's current Debt-to-EBITDA is 5.34, which is 394% above median its own 10-year median of 1.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SunWay Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, SunWay Biotech Co (ROCO:1271) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$113.57, compared to a current price of NT$59.50 — trading 47.6% below its estimated fair value. The current Debt-to-EBITDA is 5.34, which is 394% above median its 10-year median of 1.08 and 156.7% above the Consumer Packaged Goods industry median of 2.08. SunWay Biotech Co's overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For SunWay Biotech Co (ROCO:1271), the current Debt-to-EBITDA is 5.34 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SunWay Biotech Co (ROCO:1271) Overvalued in 2026?
Based on GuruFocus' analysis, SunWay Biotech Co stock appears to be undervalued.
The current stock price of NT$59.50 is trading 47.6% below its estimated GF Value™ of NT$113.57.
GuruFocus considers SunWay Biotech Co to be Significantly Undervalued.
Key valuation signals for ROCO:1271:
Debt-to-EBITDA: 5.34 (394% above median its 10-year median of 1.08)
GF Value™: NT$113.57 vs. price of NT$59.50 (47.6% below fair value)
Industry Position: 156.7% above the Consumer Packaged Goods median (#1316 of 1565)
No single metric tells the full story. See the ROCO:1271 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SunWay Biotech Co Ltd is engaged in the research, design and manufacturing of Monascus purpureus NTU 568, Lactobacillus paracasei subsp, paracasei NTU 101, and the related products.
82GF Score
Get the complete analysis for ROCO:1271
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1271 has been successfully added to your 
